Grifols (GRFS) Short-term Investments (2009 - 2025)
Grifols (GRFS) posted Short-term Investments of $41.9 million for Q4 2025, up 553.59% quarter-over-quarter from $6.4 million in Q4 2024, and up 553.59% year-on-year from $6.4 million in Q4 2024.
Grifols (GRFS) Short-term Investments (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Short-term Investments for 16 consecutive years, with $41.9 million the latest figure, recorded in Q4 2025.
- Short-term Investments for Q4 2025 came in at $41.9 million, up 553.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $41.9 million (up 553.59% YoY), and the FY2025 annual result was $41.9 million, up 553.59% from the prior year.
- Short-term Investments was $41.9 million for Q4 2025 at Grifols, up from $6.4 million in the prior quarter.
- Over five years, Short-term Investments peaked at $2.3 billion in Q4 2021 and troughed at $6.4 million in Q4 2024.
- Average Short-term Investments over 5 years is $488.0 million, with a median of $41.9 million recorded in 2025.
- Year-over-year, Short-term Investments plunged 98.08% in 2022 and surged 553.59% in 2025.
- Over 5 years, Short-term Investments stood at $2.3 billion in 2021, then slumped by 98.08% to $44.5 million in 2022, then slumped by 42.89% to $25.4 million in 2023, then slumped by 74.8% to $6.4 million in 2024, then surged by 553.59% to $41.9 million in 2025.
- Per Business Quant data, the three most recent Short-term Investments figures were $41.9 million in Q4 2025, $6.4 million in Q4 2024, and $25.4 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.91 Mn |
| Dec 31, 2024 | 6.41 Mn |
| Dec 31, 2023 | 25.44 Mn |
| Dec 31, 2022 | 44.55 Mn |
| Dec 31, 2021 | 2.32 Bn |
| Sep 30, 2020 | 14.35 Mn |
| Mar 31, 2020 | 14.39 Mn |
| Dec 31, 2019 | 1.91 Bn |
| Sep 30, 2019 | 3.08 Mn |
| Mar 31, 2019 | 202.58 Mn |
| Dec 31, 2018 | 22.75 Mn |
| Sep 30, 2018 | 59.78 Mn |
| Mar 31, 2018 | 12.92 Mn |
| Dec 31, 2017 | 12.64 Mn |
| Jun 30, 2017 | 13.60 Mn |
| Dec 31, 2016 | 2.79 Mn |
| Sep 30, 2016 | 1.99 Mn |
| Jun 30, 2016 | 2.24 Mn |
| Mar 31, 2016 | 3.31 Mn |
| Dec 31, 2015 | 1.42 Mn |